STRUCTURAL CHANGES IN REGIONAL LYMPH NODES IN EXPERIMENTAL PULMONARY FIBROSIS
Keywords:
pulmonary fibrosis, regional lymph nodes, laboratory experiment
Abstract
Pulmonary fibrosis is a pathological process in the lungs characterized by refractoriness to therapy and high mortality rates, it represents a heterogeneous group of disorders with progressive and irreversible destruction of lung architectonics due to scarring, which ultimately leads to organ dysfunction, gas exchange disorders and death due to respiratory failure. [D.V. Bestaev, 2014]. But changes in the lymph nodes during the fibrous process of the lung tissue are poorly understood. The article presents a review of the literature on structural changes in regional lymph nodes that occur in experimental pulmonary fibrosis.
References
1. Avdeev S.N., Chikina S.Yu., Nagatkina O.V. Idiopathic pulmonary fibrosis: new international clinical guidelines. Pulmonology. 2019; 29(5):525-552.
2. Aitbayev K.A., Murkamilov I.T., Fomin V.V., Kudaibergenova I.O., Murkamilova Zh.A., Yusupov F.A. Pulmonary fibrosis as a consequence of the COVID-19 pandemic // Bulletin of Science and Practice. 2021. №5.
3. Bestaev David Vladimirovich, Karateev Dmitry Evgenievich, Nasonov Evgeny Lvovich Tactics of management of patients with pulmonary fibrosis // Clinical medicine. 2014. №2.
4. Voznesensky N.A., Chuchalin A.G., Antonov N.S. Nitric oxide and lungs. Pulmonology. 1998;(2):6-10.
5. Degtyar Yu.V. Morphology of lung tissue damage during inhalation and non-inhalation intake of toxins into the body: Abstract of the dissertation of the Candidate of Medical Sciences. Volgograd, 2006. - 22 p.
6. Esipova I.K. Pathological anatomy of the lungs. M., Medicine, 1979.-183 p.
7. Zolotnitskaya V.P. Disorders of pulmonary circulation in chronic obstructive pulmonary pathology. Abstract of the dissertation of Dr. biol.Sciences, St. Petersburg, 2017. – 52 p.
8. Nazarov N.N., Dzhumabaev E.S., Gafurov Z.K., Makhmudov A.B., Melikuziev E.B., Kosimov F.P., Ubaydullaev F.K. The validity of regional lymphotropic therapy in the treatment of bronchiectatic disease // Scientific and practical conference "St. Petersburg Lymphological Forum" 2017
9. Kogan E.A., Sekamova S.M., Kornev B.M., etc. Intercellular interactions in the morphogenesis of initial lesions and sclerosis in interstitial lung diseases // Vestn. RAMS. 1995. - No. 5. - pp. 23-30.
10. Kogan E.A. Fibrosing alveolitis — modern aspects of the problem // Arch. pathology. 1995. - No. 4. - pp. 5-11.
11. Polosukhin V.V. Morphogenesis of destructive and regenerative processes of the lungs and reactivity of regional lymphatic structures in inflammation and endobrochial laser therapy. Autoref-t diss. doctors of medical sciences. Chelyabinsk, 1997. - p.2
12. Titova O.N., Preobrazhenskaya T.N., Lebedeva E.S., Kuzubova N.A., Markizova N.F. Damage to the bronchopulmonary apparatus as a result of exposure to toxic products of fires and environmentally unfavorable factors of chemical nature (nitrogen oxides). Biomedical and socio-psychological problems of safety in emergency situations. 2014;(2):61-68.
13. Shostak N.A., Klimenko A.A., Kondrashov A.A. Interstitial lung diseases: key targets for therapy. Clinician 2017;11(3-4):10-6
14. Burnham E. L., Janssen W. J., Riches D. W., Moss M., Downey G. P. The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance // European respiratory journal. 2014. V. 43. №1. P. 276-285.
15. Cardinal-Fernández P., Lorente J. A., Ballén-Barragán A., Matute-Bello G. Acute respiratory distress syndrome and diffuse alveolar damage. New insights on a complex relationship // Annals of the American Thoracic Society. 2017. V. 14. №6. P. 844-850.
16. Davies H.R., Richeldi L., Walters E.H. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003;
17. Environmental Protection Agency. Draft Integrated Science Assessment for Nitrogen Oxides Health Criteria. 2013. – URL: www.federalregister.gov.
18. Gay S.E., Kazerooni E.A., Toews G.B., Lynch J.P. III, Gross B.H., Cascade P.N. et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am. J. Respir. Crit. Care Med. 1998; 157: 1063—72.
19. Geiser T. Idiopathic pulmonary fibrosis a disorder of alveolar wound repair? // Swiss Med. Wkly. - 2003. - Vol. 133. - NN29-30. - P. 405-411.
20. George P. M., Wells A. U., Jenkins R. G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy // The Lancet Respiratory Medicine. 2020.
21. Maher T.M. Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. Clin Chest Med 2012;33(1):69–83. DOI: 10.1016/j. ccm. 2011.11.002.
22. Peters S.G., McDougall J.C., Douglas W.W., Coles D.T., DeRemee R.A. Colchicine in the treatment of pulmonary fibrosis. Chest. 1993; 103: 101—4.
23. Richeldi L., Davies H.R., Ferrara G., Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003; (3): CD002880.
24. Э. М., Ш. ., Ш. Ш., М. ., & М. М, Б. . (2022). ФАРМАКОЛОГИЧЕСКИЕ СВОЙСТВА РАСТИТЕЛЬНОГО ЛЕКАРСТВЕННОГО СРЕДСТВА ПЛОДОВ БОЯРЫШНИКА, ЕГО ГИПОТЕНЗИВНОЕ ДЕЙСВИЕ ПРИ КОМПЛЕКСНОЙ ТЕРАПИИ. IJTIMOIY FANLARDA INNOVASIYA ONLAYN ILMIY JURNALI, 114–117. Retrieved from http://sciencebox.uz/index.php/jis/article/view/1374
25. Ahrorovna, K. D., & Dilshodovich, K. M. (2021). MORPHOGENESIS OF THE THYMUS OF LABORATORY ANIMALS UNDER THE INFLUENCE OF VARIOUS FACTORS. Web of Scientist: International Scientific Research Journal, 2(04), 483-488.
26. Sanoev, B. A., & Mukhidova, G. H. (2022). CHARACTERISTIC MORPHOLOGICAL CHANGES OF SECONDARY PLACENTARY DEFICIENCY. Scientific progress, 3(4), 105-111.
27. Khasanova, D. A. (2021). MICROSCOPIC STRUCTURE OF THE RAT SPLEEN DURING THE INTRODUCTION OF A GENETICALLY MODIFIED PRODUCT. British Medical Journal, 1(1.2).
28. Khasanova, D. A. (2021). HISTOLOGICAL STRUCTURE OF THE RAT SPLEEN IN EARLY POSTNATAL ONTOGENESIS. Art of Medicine. International Medical Scientific Journal, 1(2).
29. Хасанова, Д. (2021). Структурно–функциональные особенности селезенки крыс в норме и при введении генно-модифицированного продукта. Общество и инновации, 2(4), 114-122.
30. Редактор журналов и конференций. (2021, 12 октября). ЭКСПЕРИМЕНТАЛЬНОЕ ИССЛЕДОВАНИЕ МОРФО-ФУНКЦИОНАЛЬНЫХ ИЗМЕНЕНИЙ В СЕМЕННИКАХ КРЫС ПРИ СТРЕССЕ. https://doi.org/10.17605/OSF.IO/RT673
31. (WHO) WHO, Coronavirus disease 2019 (COVID-19) situation report
- 98 27 April 2020, WHO Bull, 2020
2. Aitbayev K.A., Murkamilov I.T., Fomin V.V., Kudaibergenova I.O., Murkamilova Zh.A., Yusupov F.A. Pulmonary fibrosis as a consequence of the COVID-19 pandemic // Bulletin of Science and Practice. 2021. №5.
3. Bestaev David Vladimirovich, Karateev Dmitry Evgenievich, Nasonov Evgeny Lvovich Tactics of management of patients with pulmonary fibrosis // Clinical medicine. 2014. №2.
4. Voznesensky N.A., Chuchalin A.G., Antonov N.S. Nitric oxide and lungs. Pulmonology. 1998;(2):6-10.
5. Degtyar Yu.V. Morphology of lung tissue damage during inhalation and non-inhalation intake of toxins into the body: Abstract of the dissertation of the Candidate of Medical Sciences. Volgograd, 2006. - 22 p.
6. Esipova I.K. Pathological anatomy of the lungs. M., Medicine, 1979.-183 p.
7. Zolotnitskaya V.P. Disorders of pulmonary circulation in chronic obstructive pulmonary pathology. Abstract of the dissertation of Dr. biol.Sciences, St. Petersburg, 2017. – 52 p.
8. Nazarov N.N., Dzhumabaev E.S., Gafurov Z.K., Makhmudov A.B., Melikuziev E.B., Kosimov F.P., Ubaydullaev F.K. The validity of regional lymphotropic therapy in the treatment of bronchiectatic disease // Scientific and practical conference "St. Petersburg Lymphological Forum" 2017
9. Kogan E.A., Sekamova S.M., Kornev B.M., etc. Intercellular interactions in the morphogenesis of initial lesions and sclerosis in interstitial lung diseases // Vestn. RAMS. 1995. - No. 5. - pp. 23-30.
10. Kogan E.A. Fibrosing alveolitis — modern aspects of the problem // Arch. pathology. 1995. - No. 4. - pp. 5-11.
11. Polosukhin V.V. Morphogenesis of destructive and regenerative processes of the lungs and reactivity of regional lymphatic structures in inflammation and endobrochial laser therapy. Autoref-t diss. doctors of medical sciences. Chelyabinsk, 1997. - p.2
12. Titova O.N., Preobrazhenskaya T.N., Lebedeva E.S., Kuzubova N.A., Markizova N.F. Damage to the bronchopulmonary apparatus as a result of exposure to toxic products of fires and environmentally unfavorable factors of chemical nature (nitrogen oxides). Biomedical and socio-psychological problems of safety in emergency situations. 2014;(2):61-68.
13. Shostak N.A., Klimenko A.A., Kondrashov A.A. Interstitial lung diseases: key targets for therapy. Clinician 2017;11(3-4):10-6
14. Burnham E. L., Janssen W. J., Riches D. W., Moss M., Downey G. P. The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance // European respiratory journal. 2014. V. 43. №1. P. 276-285.
15. Cardinal-Fernández P., Lorente J. A., Ballén-Barragán A., Matute-Bello G. Acute respiratory distress syndrome and diffuse alveolar damage. New insights on a complex relationship // Annals of the American Thoracic Society. 2017. V. 14. №6. P. 844-850.
16. Davies H.R., Richeldi L., Walters E.H. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003;
17. Environmental Protection Agency. Draft Integrated Science Assessment for Nitrogen Oxides Health Criteria. 2013. – URL: www.federalregister.gov.
18. Gay S.E., Kazerooni E.A., Toews G.B., Lynch J.P. III, Gross B.H., Cascade P.N. et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am. J. Respir. Crit. Care Med. 1998; 157: 1063—72.
19. Geiser T. Idiopathic pulmonary fibrosis a disorder of alveolar wound repair? // Swiss Med. Wkly. - 2003. - Vol. 133. - NN29-30. - P. 405-411.
20. George P. M., Wells A. U., Jenkins R. G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy // The Lancet Respiratory Medicine. 2020.
21. Maher T.M. Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. Clin Chest Med 2012;33(1):69–83. DOI: 10.1016/j. ccm. 2011.11.002.
22. Peters S.G., McDougall J.C., Douglas W.W., Coles D.T., DeRemee R.A. Colchicine in the treatment of pulmonary fibrosis. Chest. 1993; 103: 101—4.
23. Richeldi L., Davies H.R., Ferrara G., Franco F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003; (3): CD002880.
24. Э. М., Ш. ., Ш. Ш., М. ., & М. М, Б. . (2022). ФАРМАКОЛОГИЧЕСКИЕ СВОЙСТВА РАСТИТЕЛЬНОГО ЛЕКАРСТВЕННОГО СРЕДСТВА ПЛОДОВ БОЯРЫШНИКА, ЕГО ГИПОТЕНЗИВНОЕ ДЕЙСВИЕ ПРИ КОМПЛЕКСНОЙ ТЕРАПИИ. IJTIMOIY FANLARDA INNOVASIYA ONLAYN ILMIY JURNALI, 114–117. Retrieved from http://sciencebox.uz/index.php/jis/article/view/1374
25. Ahrorovna, K. D., & Dilshodovich, K. M. (2021). MORPHOGENESIS OF THE THYMUS OF LABORATORY ANIMALS UNDER THE INFLUENCE OF VARIOUS FACTORS. Web of Scientist: International Scientific Research Journal, 2(04), 483-488.
26. Sanoev, B. A., & Mukhidova, G. H. (2022). CHARACTERISTIC MORPHOLOGICAL CHANGES OF SECONDARY PLACENTARY DEFICIENCY. Scientific progress, 3(4), 105-111.
27. Khasanova, D. A. (2021). MICROSCOPIC STRUCTURE OF THE RAT SPLEEN DURING THE INTRODUCTION OF A GENETICALLY MODIFIED PRODUCT. British Medical Journal, 1(1.2).
28. Khasanova, D. A. (2021). HISTOLOGICAL STRUCTURE OF THE RAT SPLEEN IN EARLY POSTNATAL ONTOGENESIS. Art of Medicine. International Medical Scientific Journal, 1(2).
29. Хасанова, Д. (2021). Структурно–функциональные особенности селезенки крыс в норме и при введении генно-модифицированного продукта. Общество и инновации, 2(4), 114-122.
30. Редактор журналов и конференций. (2021, 12 октября). ЭКСПЕРИМЕНТАЛЬНОЕ ИССЛЕДОВАНИЕ МОРФО-ФУНКЦИОНАЛЬНЫХ ИЗМЕНЕНИЙ В СЕМЕННИКАХ КРЫС ПРИ СТРЕССЕ. https://doi.org/10.17605/OSF.IO/RT673
31. (WHO) WHO, Coronavirus disease 2019 (COVID-19) situation report
- 98 27 April 2020, WHO Bull, 2020
Published
2022-06-10
How to Cite
Sharipova Elvina M., & Khodjiev Dilmurod. (2022). STRUCTURAL CHANGES IN REGIONAL LYMPH NODES IN EXPERIMENTAL PULMONARY FIBROSIS. Central Asian Journal of Medical and Natural Science, 3(3), 488-494. https://doi.org/10.17605/cajmns.v3i3.813
Issue
Section
Articles
